InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $432K+215.9% | $137K-90.0% | $1.4M-86.7% | $10.3M+3.6% | $9.9M |
| Cost of sales | $100K-23.4% | $131K-90.1% | $1.3M-72.2% | $4.7M-8.0% | $5.1M |
| Gross profit | $331K+5420.1% | $6K-87.8% | $49K-99.1% | $5.5M+16.3% | $4.7M |
| Wage and salary expense | $2.1M+0.4% | $2.1M+236.9% | $627K-82.5% | $3.6M-6.9% | $3.8M |
| Professional fees | $2.4M+65.1% | $1.5M+66.6% | $875K+87.5% | $467K-57.4% | $1.1M |
| Accounting and legal expense | $2.1M+14.6% | $1.8M+19.9% | $1.5M+81.6% | $830K+18.9% | $698K |
| Technology expense | $97K-76.6% | $416K+315.1% | $100K-89.9% | $993K+10.4% | $900K |
| General and administrative | $7.9M+18.7% | $6.7M+399.6% | $1.3M-20.9% | $1.7M-10.9% | $1.9M |
| Research and development | $2.0M-12.5% | $2.2M | — | — | — |
| Impairment loss | $26.3M | — | — | — | — |
| Total operating expenses | $42.9M+191.8% | $14.7M+230.8% | $4.4M-47.3% | $8.4M-16.0% | $10.0M |
| Operating loss | -$42.6M-189.7% | -$14.7M-234.4% | -$4.4M-50.8% | -$2.9M+44.9% | -$5.3M |
| Change in fair value of warrant liability | $909K+596.8% | -$183K-23.3% | -$148K-118.0% | $826K | — |
| Change in fair value of derivative liability | $2.3M+1173.3% | $180K | — | — | — |
| Impairment of investment | -$2.5M | — | — | — | — |
| Loss on conversion of note payable | -$53K | — | — | — | — |
| Loss on disposition of subsidiaries | -$288K | — | — | — | — |
| Interest income | $303K+123.7% | $135K+3123.8% | $4K-80.0% | $21K | — |
| Loss on disposal of asset | -$375K | — | -$2.8M | — | — |
| Interest expense | -$4.1M-205.7% | -$1.3M-16.8% | -$1.1M-240.0% | -$336K-1325.2% | -$24K |
| Total non-operating expense | -$916K+77.5% | -$4.1M+0.2% | -$4.1M-897.3% | $513K+2272.6% | -$24K |
| Net loss from continuing operations | -$43.5M-131.7% | -$18.8M-121.4% | -$8.5M-252.9% | -$2.4M | — |
| Benefit / (provision) for income taxes | $2.0M+273.3% | $534K | — | — | — |
| Net loss from continuing operations, net of tax | -$41.5M-127.5% | -$18.2M-115.1% | -$8.5M-252.9% | -$2.4M | — |
| Net income from discontinued operations, net of tax | $27.3M | — | -$9.4M-521.4% | -$1.5M | — |
| Net (loss) income | -$41.5M-557.9% | $9.1M+150.8% | -$17.8M-413.9% | -$3.5M+34.7% | -$5.3M |
| Basic | $15.3M+354.7% | $3.4M+341.8% | $764K+35.3% | $565K | — |
| Diluted | $15.3M+320.1% | $3.7M+53.4% | $2.4M+320.3% | $567K | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Scienture granted 180-day extension by Nasdaq to regain compliance